Venus Remedies Ltd - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pls find enclosed herewith a copy of press release titled 'Venus Remedies enters consumer healthcare business with R3SET launch'.15-07-2021
15-07-2021
VENUS REMEDIES LTD. - 526953 - Shareholding for the Period Ended June 30, 2021
Venus Remedies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here10-07-2021
VENUS REMEDIES LTD. - 526953 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance under regulation 74(5) of SEBi DP Regulations, 201809-07-2021
VENUS REMEDIES LTD. - 526953 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 017170 Name of the Signatory :- NehaDesignation :- Company Secretary and Compliance Officer09-07-2021
Venus Remedies Ltd - 526953 - Closure of Trading Window
Pursuant to the Code of Conduct adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, this is to inform that the trading window for dealing in equity shares of the Company will remain closed for all Designated Persons of the Company, as defined under the said Regulations, from July 1, 2021 till 48 hours from the declaration of the Unaudited Financial Results for the Quarter ending June 30, 2021.30-06-2021
Venus Remedies wins legal battle against French firm for paracetamol patent
The Indian drug firm had initiated the legal battle in order to remove any patent hurdle in manufacturing of intravenous paracetamol solution in the country.17-06-2021
Venus Remedies Ltd - 526953 - Disclosure Of Related Party Transaction Pursuant To Regulation 23(9) Of The SEBI ( Listing Obligations & Disclosures Requirements) Regulations, 2015
Pursuant to regulation 23(9) of the SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015, kindly find enclosed herewith a disclosure on related party transaction on Standalone and Consolidated basis for the year ended on 31st March 2021.08-06-2021
VENUS REMEDIES LTD. - 526953 - Declaration With Respect To Audit Report With Unmodified Opinion For Audited Standalone And Consolidated Financial Year Ended 31St March 2021
Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm and declare that the Statutory Auditors of the Company, have submitted the Auditors report on Standalone and Consolidate Financial results of the Company for the quarter and year ended on 31st March, 2021 with the unmodified opinion.08-06-2021
Venus Remedies Ltd - 526953 - Shareholding for the Period Ended June 07, 2021
Venus Remedies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 07, 2021. For more details, kindly Click here07-06-2021
Venus Remedies Ltd - 526953 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pawan Chaudhary04-06-2021